Insilico Medicine announced a strategic collaboration with Takeda to apply its proprietary Pharma.AI end-to-end platform to discover and advance drug candidates across Takeda’s therapeutic areas.
The collaboration is structured to use advanced generative models from early design stages to improve molecule quality and optimize efficacy and safety. Insilico will lead AI-driven discovery to identify molecules that meet predefined scientific and early development criteria, while Takeda will use its global development capabilities to advance selected candidates through clinical validation.
Under the agreement, Insilico will receive approximately $60 million in project initiation fees, near-term payments and milestones, and is eligible for success-based preclinical, clinical, commercial and sales milestone payments that could bring total deal value to about $600 million, plus tiered royalties on future sales.
The agreement grants Takeda exclusive worldwide rights to develop, manufacture and commercialize therapeutics selected through the collaboration. Insilico, the company claims, was listed on the Main Board of the Hong Kong Stock Exchange on 30 December 2025 under the stock code 03696.HK.
